Breast and Gynecologic Cancer Prevention in Low-Resource Countries

  • William Kofi Bosu
  • Terri L. Cornelison
  • Brandy M. Heckman-Stoddard


This chapter focuses on the prevention of breast, ovarian, endometrial, and cervical cancers through a discussion of risk factors and active interventions for prevention. The priority options available to most low resource countries (LRCs) are to improve health lifestyles and to promote early diagnosis of symptomatic cancer. Avoiding alcohol misuse, smoking, adult weight gain, obesity, physical inactivity, shortened or absent duration of breastfeeding are amenable to individual or group actions. Enacting and enforcing national legislation to reduce lifetime exposure to risk factors and to introduce and expand HPV vaccination programs are needed. The benefits of chemoprevention studies may only be felt in LRCs when low cost options are proven effective in locally relevant resource-limited settings.


Breast Cancer Ovarian Cancer Cervical Cancer Breast Cancer Risk Endometrial Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



American Heart Association


Aromatase inhibitors


Breast Cancer Prevention Trial


Breast Global Health Initiative


Bilateral prophylactic mastectomy


Breast self-examination


Bilateral salpingo-oophorectomy


Clinical breast examination


Centers for Disease Control and Prevention


Contralateral prophylactic mastectomy




Depot medroxyprogesterone acetate


Extremely low frequency-electromagnetic fields


European Prospective Investigation into Cancer and Nutrition


Estrogen receptor


Hereditary breast and ovarian cancer


Food and Drug Administration


Hereditary nonpolyposis colorectal cancer


Human papilloma virus


Hormonal replacement therapy


International Agency for Research on Cancer


International Breast Cancer Intervention Study


Institute of Medicine


Low resource countries


Multiple Outcomes of Raloxifene Evaluation


Non-communicable disease


National Surgical Adjuvant Breast and Bowel Project


Oral contraceptives


Poly adenosine diphosphate ribose polymerase


Prostate, lung, colorectal, and ­ovarian


Randomized controlled trials


Selective estrogen receptor modulators


Study of Tamoxifen and Raloxifene


United States


US Preventive Services Task Force


Venous thromboembolic events


World Cancer Research Fund


Women’s Health initiative


  1. 1.
    Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606–16.PubMedGoogle Scholar
  2. 2.
    Colditz GA, Kaphingst KA, Hankinson SE, Rosner B. Family history and risk of breast cancer: nurses’ health study. Breast Cancer Res Treat. 2012;133:1097–104.PubMedGoogle Scholar
  3. 3.
    Okobia M et al. Case–control study of risk factors for breast cancer in Nigerian women. Int J Cancer. 2006;119:2179–85.PubMedGoogle Scholar
  4. 4.
    Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998;7:1133–44.PubMedGoogle Scholar
  5. 5.
    Barnes BB, Steindorf K, Hein R, Flesch-Janys D, Chang-Claude J. Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors. Cancer Epidemiol. 2011;35:345–52.PubMedGoogle Scholar
  6. 6.
    Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M, Comparative Risk Assessment collaborating group (Cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366:1784–93.PubMedGoogle Scholar
  7. 7.
    International Agency for Research on Cancer. IARC handbooks of cancer prevention, Weight control and physical activity, vol. 6. Lyon: IARC; 2002.Google Scholar
  8. 8.
    Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.PubMedGoogle Scholar
  9. 9.
    Ravdin PM et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4.PubMedGoogle Scholar
  10. 10.
    Chlebowski RT et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol. 2010;28:2690–7.PubMedGoogle Scholar
  11. 11.
    Jordan VC, Ford LG. Paradoxical clinical effect of estrogen on breast cancer risk: a “new” biology of estrogen-induced apoptosis. Cancer Prev Res (Phila). 2011;4:633–7.Google Scholar
  12. 12.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–27.Google Scholar
  13. 13.
    Hunter DJ et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev. 2010;19:2496–502.PubMedGoogle Scholar
  14. 14.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360:187–95.Google Scholar
  15. 15.
    Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006;8:R43.PubMedGoogle Scholar
  16. 16.
    Lacey Jr JV et al. Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. BMC Cancer. 2009;9:84.PubMedGoogle Scholar
  17. 17.
    IOM (Institute of Medicine). Breast cancer and the environment: a life course approach. Washington, DC: The National Academies Press; 2012.Google Scholar
  18. 18.
    Baan R et al. A review of human carcinogens–Part F: chemical agents and related occupations. Lancet Oncol. 2009;10:1143–4.PubMedGoogle Scholar
  19. 19.
    Straif K et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8:1065–6.PubMedGoogle Scholar
  20. 20.
    The Lancet. Breast cancer on the night shift. Lancet. 2009;373:1054.Google Scholar
  21. 21.
    International Agency for Research on Cancer. Ionizing radiation, Part 1: X- and gamma (γ)-radiation, and neutrons, IARC monographs on the evaluation of carcinogenic risks to humans, vol. 75. Lyon: IARC; 2000.Google Scholar
  22. 22.
    American Cancer Society. Cancer facts and figures 2012. In: American Cancer Society, editor. Atlanta, GA; 2012.Google Scholar
  23. 23.
    Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology. 1998;12:399–406; discussion 409–10, 413.PubMedGoogle Scholar
  24. 24.
    Aarnio M et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214–8.PubMedGoogle Scholar
  25. 25.
    Ziel HK. Estrogen’s role in endometrial cancer. Obstet Gynecol. 1982;60:509–15.PubMedGoogle Scholar
  26. 26.
    Yang HS, Yoon C, Myung SK, Park SM. Effect of obesity on survival of women with epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. Int J Gynecol Cancer. 2011;21:1525–32.PubMedGoogle Scholar
  27. 27.
    Olsen CM et al. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007;43:690–709.PubMedGoogle Scholar
  28. 28.
    Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol. 2008;108(3):641–51.PubMedGoogle Scholar
  29. 29.
    Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1739–48.PubMedGoogle Scholar
  30. 30.
    Lacey Jr JV, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst. 2006;98:1397–405.PubMedGoogle Scholar
  31. 31.
    Gertig DM et al. Prospective study of talc use and ovarian cancer. J Natl Cancer Inst. 2000;92:249–52.PubMedGoogle Scholar
  32. 32.
    Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, et al. Ovarian cancer and smoking: individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13:946–56.PubMedGoogle Scholar
  33. 33.
    Hankinson SE et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA. 1993;270:2813–8.PubMedGoogle Scholar
  34. 34.
    Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer Epidemiol Biomarkers Prev. 1996;5:933–5.PubMedGoogle Scholar
  35. 35.
    Wilailak S et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case–control study. BJOG. 2012;119:672–7.PubMedGoogle Scholar
  36. 36.
    Daly M, Obrams GI. Epidemiology and risk assessment for ovarian cancer. Semin Oncol. 1998;25:255–64.PubMedGoogle Scholar
  37. 37.
    Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. Semin Oncol. 1984;11:209–26.PubMedGoogle Scholar
  38. 38.
    Kurta ML et al. Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study. Cancer Epidemiol Biomarkers Prev. 2012;21:1282–92.PubMedGoogle Scholar
  39. 39.
    Trope CG, Sabbatini PJ, Zaino RJ. Corpus: epithelial tumors. In: Hoskins WJ et al., editors. Principles and practice of gynecologic oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.Google Scholar
  40. 40.
    Tretli S, Magnus K. Height and weight in relation to uterine corpus cancer morbidity and mortality. A follow-up study of 570,000 women in Norway. Int J Cancer. 1990;46:165–72.PubMedGoogle Scholar
  41. 41.
    Vasen HF et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996;110:1020–7.PubMedGoogle Scholar
  42. 42.
    Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med. 1994;96:516–20.PubMedGoogle Scholar
  43. 43.
    Dunlop MG et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997;6:105–10.PubMedGoogle Scholar
  44. 44.
    Lancaster JM et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107:159–62.PubMedGoogle Scholar
  45. 45.
    Burke W et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: I. hereditary nonpolyposis colon cancer. JAMA. 1997;277:915–9.PubMedGoogle Scholar
  46. 46.
    Mehasseb MK, Latimer JA. Controversies in the management of endometrial carcinoma: an update. Obstet Gynecol Int. 2012;2012:676032. doi: 10.1155/2012/676032.PubMedGoogle Scholar
  47. 47.
    Fisher B et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.PubMedGoogle Scholar
  48. 48.
    Fisher B et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.PubMedGoogle Scholar
  49. 49.
    Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99:283–90.PubMedGoogle Scholar
  50. 50.
    Powles T et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98–101.PubMedGoogle Scholar
  51. 51.
    Veronesi U et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998;352:93–7.PubMedGoogle Scholar
  52. 52.
    Veronesi U et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99:727–37.PubMedGoogle Scholar
  53. 53.
    Cuzick J. Continuation of the International Breast Cancer Intervention Study (IBIS). Eur J Cancer. 1998;34:1647–8.PubMedGoogle Scholar
  54. 54.
    Cuzick J et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360:817–24.PubMedGoogle Scholar
  55. 55.
    Merritt MA, Cramer DW. Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark. 2011;9:287–305.Google Scholar
  56. 56.
    Parazzini F, La Vecchia C, Negri E, Fedele L, Balotta F. Reproductive factors and risk of endometrial cancer. Am J Obstet Gynecol. 1991;164:522–7.PubMedGoogle Scholar
  57. 57.
    Sun XW et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997;337:1343–9.PubMedGoogle Scholar
  58. 58.
    Castle PE, Giuliano AR. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients—assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr. 2003;31:29–34.PubMedGoogle Scholar
  59. 59.
    Smit JS et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361:1159–67.Google Scholar
  60. 60.
    Romaguera D et al. Is concordance with World Cancer Research Fund/American Institute for Cancer Research guidelines for cancer prevention related to subsequent risk of cancer? Results from the EPIC study. Am J Clin Nutr. 2012;96:150–63.PubMedGoogle Scholar
  61. 61.
    Secretan B et al. A review of human carcinogens? Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009;10:1033–4.PubMedGoogle Scholar
  62. 62.
    Luo J et al. Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. BMJ. 2011;342:d1016.PubMedGoogle Scholar
  63. 63.
    DeRoo LA, Cummings P, Mueller BA. Smoking before the first pregnancy and the risk of breast cancer: a meta-analysis. Am J Epidemiol. 2011;174:390–402.PubMedGoogle Scholar
  64. 64.
    World Health Organization. WHO report on the global tobacco epidemic, 2008: the MPOWER package. Geneva: WHO; 2008.Google Scholar
  65. 65.
    World Health Organization. WHO framework convention on tobacco control. Geneva: WHO; 2003.Google Scholar
  66. 66.
    Owusu-Dabo E, Lewis S, McNeill A, Gilmore A, Britton J. Support for smoke-free policy, and awareness of tobacco health effects and use of smoking cessation therapy in a developing country. BMC Public Health. 2011;11:572.PubMedGoogle Scholar
  67. 67.
    World Health Organization. Study group on economically sustainable alternatives to tobacco growing (in relation to Articles 17 and 18 of the Convention). FCTC/COP/3/11. Conference of the Parties to the WHO framework convention on tobacco control third session, Durban, 17–22 Nov 2008.Google Scholar
  68. 68.
    Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58515 women with breast cancer and 95067 women without the disease. Br J Cancer. 2002;87:1234–45.Google Scholar
  69. 69.
    McCormack VA, Boffetta P. Today’s lifestyles, tomorrow’s cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries. Ann Oncol. 2011;22:2349–57.PubMedGoogle Scholar
  70. 70.
    British Medical Association. Alcohol misuse: tackling the UK epidemic. Feb 2008.Google Scholar
  71. 71.
    World Cancer Research Fund and American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. London: AICR; 2007.Google Scholar
  72. 72.
    Bakke Ø, Endal D. Alcohol policies out of context: drinks industry supplanting government role in alcohol policies in Sub-Saharan Africa. Addiction. 2010;105:22–8.PubMedGoogle Scholar
  73. 73.
    World Cancer Research Fund/American Institute of Cancer Research. The associations between food, nutrition and physical activity and the risk of breast cancer. Washington, DC: AICR; 2008.Google Scholar
  74. 74.
    Awatef M et al. Physical activity reduces breast cancer risk: a case–control study in Tunisia. Cancer Epidemiol. 2011;35:540–4.PubMedGoogle Scholar
  75. 75.
    Church TS, Earnest CP, Skinner JS, Blair SN. Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. JAMA. 2007;297:2081–91.PubMedGoogle Scholar
  76. 76.
    Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11:1531–43.PubMedGoogle Scholar
  77. 77.
    Arem H et al. Physical activity and endometrial cancer in a population-based case–control study. Cancer Causes Control. 2011;22:219–26.PubMedGoogle Scholar
  78. 78.
    World Health Organization & Food and Agricultural Organization. Diet, nutrition and the prevention of chronic diseases: report of a joint WHO/FAO expert consultation. Geneva: WHO; 2003.Google Scholar
  79. 79.
    American Heart Association Nutrition Committee et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82–96.Google Scholar
  80. 80.
    Mytton OT, Clarke D, Rayner M. Taxing unhealthy food and drinks to improve health. BMJ. 2012;344:e2931.PubMedGoogle Scholar
  81. 81.
    World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: WHO; 2011.Google Scholar
  82. 82.
    Cuzick J. Use of selective estrogen receptor modulators in the prevention of breast cancer: an overview of the randomized trials. Cancer Res 2009;69; Abstract no. 905.Google Scholar
  83. 83.
    Cuzick J et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496–503.PubMedGoogle Scholar
  84. 84.
    Cummings SR et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA. 1999;281:2189–97; Erratum in: JAMA 1999;2282(2122):2124.PubMedGoogle Scholar
  85. 85.
    Vogel VG et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3:696–706.Google Scholar
  86. 86.
    Iqbal J et al. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev. 2012;38:318–28.PubMedGoogle Scholar
  87. 87.
    Gail MH et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829–46.PubMedGoogle Scholar
  88. 88.
    Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28:3090–5.PubMedGoogle Scholar
  89. 89.
    Waters EA, Cronin KA, Graubard BI, Han PK, Freedman AN. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev. 2010;19:443–6.PubMedGoogle Scholar
  90. 90.
    Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol. 2005;23:1636–43.PubMedGoogle Scholar
  91. 91.
    Goss PE et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91.PubMedGoogle Scholar
  92. 92.
    Bozovic-Spasojevic I, Azambuja E, McCaskill-Stevens W, Dinh P, Cardoso F. Chemoprevention for breast cancer. Cancer Treat Rev. 2012;38:329–39.PubMedGoogle Scholar
  93. 93.
    Chlebowski RT et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28:3582–90.PubMedGoogle Scholar
  94. 94.
    Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010;28:3577–81.PubMedGoogle Scholar
  95. 95.
    Rothwell PM et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602–12.PubMedGoogle Scholar
  96. 96.
    Rothwell PM et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591–601.PubMedGoogle Scholar
  97. 97.
    Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc. 2006;81:1290–302.PubMedGoogle Scholar
  98. 98.
    Cogliano V et al. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005;6:552–3.PubMedGoogle Scholar
  99. 99.
    World Health Organization. Carcinogenicity of combined hormonal contraceptives and combined menopausal treatment. WHO, HRP, Sept 2005.Google Scholar
  100. 100.
    Kim DU, Min JW, Kim YM, Chang MC. Estimating the risks and benefits of tamoxifen for prophylactic breast cancer chemoprevention in Korea. J Breast Cancer. 2012;15:51–6.PubMedGoogle Scholar
  101. 101.
    Early Breast Cancer Trialists’ Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.Google Scholar
  102. 102.
    Uray IP, Brown PH. Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res. 2011;188:147–62.PubMedGoogle Scholar
  103. 103.
    Anyanwu SNC, Egwuonwu OA, Ihekwoaba EC. Acceptance and adherence to treatment among breast cancer patients in Eastern Nigeria. Breast. 2011;20:S51–5.PubMedGoogle Scholar
  104. 104.
    Salem DS, Kamal RM, Helal MH, Hamed ST, Abdelrazek NA, Said NH, et al. Women Health Outreach Program; a New Experience for all Egyptian Women. J Egypt Natl Canc Inst. 2008;20:313–22.PubMedGoogle Scholar
  105. 105.
    Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006;71:1–9.PubMedGoogle Scholar
  106. 106.
    Sasano H, Suzuki T. Chemoprevention of breast cancer among Asian women—its perspective and problems. Biomed Pharmacother. 2006;60:266–8.PubMedGoogle Scholar
  107. 107.
    Coopey SB, Mazzola E, Buckley JM et al. Clarifying the risk of breast cancer in women with atypical breast lesions. San Antonio Breast Cancer Symposium. 2011; Abstract S4–4.Google Scholar
  108. 108.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047–59.Google Scholar
  109. 109.
    Odiari EA, Chambers AN. Perceptions, attitudes, and self-management of natural menopausal symptoms in Ghanaian women. Health Care Women Int. 2012;33:560–74.PubMedGoogle Scholar
  110. 110.
    Im EO, Ko Y, Hwang H, Chee W. “Symptom-specific or holistic”: menopausal symptom management. Health Care Women Int. 2012;33:575–92.PubMedGoogle Scholar
  111. 111.
    LaMontagne DS et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89:821–30B.PubMedGoogle Scholar
  112. 112.
    Bello FA, Enabor OO, Adewole IF. Human papilloma virus vaccination for control of cervical cancer: a challenge for developing countries. Afr J Reprod Health. 2011;15:25–30.PubMedGoogle Scholar
  113. 113.
    Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol. 2011;12:477–88.PubMedGoogle Scholar
  114. 114.
    Ghoussaini M et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet. 2012;44:312–8.PubMedGoogle Scholar
  115. 115.
    Balmaña J, Díez O, Rubio IT, Cardoso F, ESMO Guidelines Working Group. BRCA in breast cancer: ESMO clinical practice guidelines. Ann Oncol. 2011;22:31–4.Google Scholar
  116. 116.
    Hilgart JS, Coles B, Iredale R. Cancer genetic risk assessment for individuals at risk of familial breast cancer. Cochrane Database Syst Rev;2012:CD003721.Google Scholar
  117. 117.
    Herrinton LJ et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23:4275–86.PubMedGoogle Scholar
  118. 118.
    Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010;CD002748.Google Scholar
  119. 119.
    Brewster AM et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 2012;118:5637–43.PubMedGoogle Scholar
  120. 120.
    Rebbeck TR et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616–22.PubMedGoogle Scholar
  121. 121.
    Clegg-Lamptey JNA, Hodasi WM. A study of breast cancer in Korle Bu Teaching Hospital: assessing the impact of health education. Ghana Med J. 2007;41:72–7.PubMedGoogle Scholar
  122. 122.
    Corbex M, Burton R, Sancho-Garnier H. Breast cancer early detection methods for low and middle income countries, a review of the evidence. Breast. 2012;21:428–34.PubMedGoogle Scholar
  123. 123.
    Harford JB. Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all. Lancet Oncol. 2011;12:306–12.PubMedGoogle Scholar
  124. 124.
    World Health Organization. Cancer control: knowledge into action. WHO guide for effective programmes, module 3. Early detection. Geneva: WHO; 2007.Google Scholar
  125. 125.
    Smith RA et al. Breast cancer in limited resource countries: early detection and access to care. Breast J. 2006;12:S16–26.PubMedGoogle Scholar
  126. 126.
    Anderson BO. Understanding social obstacles to early breast cancer detection is critical to improving breast cancer outcome in low- and middle-resource countries. Cancer. 2010;116:4436–9.PubMedGoogle Scholar
  127. 127.
    Landolsi A et al. Reasons of diagnostic delay of breast cancer in Tunisian women (160 patients in the central region of Tunisia). Tunis Med. 2010;88:894–7.PubMedGoogle Scholar
  128. 128.
    Dye TD et al. Complex care systems in developing countries: breast cancer patient navigation in Ethiopia. Cancer. 2010;116:577–85.PubMedGoogle Scholar
  129. 129.
    Mousa SM, Seifeldin IA, Hablas A, Elbana ES, Soliman AS. Patterns of seeking medical care among Egyptian breast cancer patients: relationship to late-stage presentation. Breast. 2011;20:555–61.PubMedGoogle Scholar
  130. 130.
    Clegg-Lamptey J, Dakubo J, Attobra YN. Why do breast cancer patients report late or abscond during treatment in Ghana? A pilot study. Ghana Med J. 2009;43:127–31.PubMedGoogle Scholar
  131. 131.
    Thornton H, Pillarisetti RR. ‘Breast awareness’ and ‘breast self-examination’ are not the same. What do these terms mean? Why are they confused? What can we do? Eur J Cancer. 2008;44:2118–21.PubMedGoogle Scholar
  132. 132.
    Ghanem S et al. Knowledge of risk factors, beliefs and practices of female healthcare professionals towards breast cancer, Morocco. Pan Afr Med J. 2011;10:21.PubMedGoogle Scholar
  133. 133.
    Ibrahim NA, Odusanya OO. Knowledge of risk factors, beliefs and practices of female healthcare professionals towards breast cancer in a tertiary institution in Lagos, Nigeria. BMC Cancer. 2009;9:76.PubMedGoogle Scholar
  134. 134.
    Nafissi N, Saghafinia M, Motamedi MH, Akbari ME. A survey of breast cancer knowledge and attitude in Iranian women. J Cancer Res Ther. 2012;8:46–9.PubMedGoogle Scholar
  135. 135.
    Opoku SY, Benwell M, Yarney J. Knowledge, attitudes, beliefs, behaviour and breast cancer screening practices in Ghana, West Africa. Pan Afr Med J. 2012;11:28.PubMedGoogle Scholar
  136. 136.
    Mayo R, Hunter A. Fatalism toward breast cancer among the women of Ghana. Health Care Women Int. 2003;24:608–16.PubMedGoogle Scholar
  137. 137.
    De Ver Dye T et al. A mixed-method assessment of beliefs and practice around breast cancer in Ethiopia: implications for public health programming and cancer control. Glob Public Health. 2011;6:719–31.PubMedGoogle Scholar
  138. 138.
    Hamad HMA. Cancer initiatives in Sudan. Ann Oncol. 2006;17:viii32–6.PubMedGoogle Scholar
  139. 139.
    Ibrahim NA, Oludara MA. Socio-demographic factors and reasons associated with delay in breast cancer presentation: a study in Nigerian women. Breast Cancer Res. 2012;21:416–8.Google Scholar
  140. 140.
    Burson AM et al. Clinical and epidemiologic profile of breast cancer in Tanzania. Breast Dis. 2010;31:33–41.PubMedGoogle Scholar
  141. 141.
    Kreps GL, Sivaram R. Strategic health communication across the continuum of breast cancer care in limited-resource countries. Cancer. 2008;113:2331–7.PubMedGoogle Scholar
  142. 142.
    The Lancet Oncology. Breast-cancer awareness: too much of a good thing? Lancet Oncol. 2007;8:1041.Google Scholar
  143. 143.
    Hackshaw AK, Paul EA. Breast self-examination and death from breast cancer: a meta-analysis. Br J Cancer. 2003;88:1047–53.PubMedGoogle Scholar
  144. 144.
    Thomas DB et al. Randomised trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst. 2002;94:1445–57.PubMedGoogle Scholar
  145. 145.
    Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev 2003;CD14003373.Google Scholar
  146. 146.
    Nelson HD et al. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:W237–742.Google Scholar
  147. 147.
    Semiglazov VF et al. Results of a prospective randomized investigation [Russia (St.Petersburg)/WHO] to evaluate the significance of self-examination for the early detection of breast cancer. Vopr Onkol. 2003;49:434–41 [In Russian].PubMedGoogle Scholar
  148. 148.
    Shalini, Varghese D, Nayak M. Awareness and impact of education on breast self examination among college going girls. Indian J Palliat Care 2011;17:150–4.Google Scholar
  149. 149.
    Moodi M, Mood MB, Sharifirad GR, Shahnazi H, Sharifzadeh G. Evaluation of breast self-examination program using Health Belief Model in female ­students. J Res Med Sci. 2011;16:316–22.PubMedGoogle Scholar
  150. 150.
    Shepherd JH, McInerney PA. Knowledge of breast self-examination in Sierra Leone. Curationis. 2007;30:38–44.PubMedGoogle Scholar
  151. 151.
    Duffy SW, Tabar L, Vitak B, Warwick J. Tumor size and breast cancer detection: what might be the effect of a less sensitive screening tool than mammography? Breast J. 2006;12:S91–5.PubMedGoogle Scholar
  152. 152.
    Miller AB, To T, Baines CJ, Wall C, for the Canadian National Breast Screening. Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50–59 years. J Natl Cancer Inst 2000;92:1490–9.Google Scholar
  153. 153.
    Sankaranarayanan R et al. Clinical trials of cancer screening in the developing world and their impact on cancer healthcare. Ann Oncol. 2011;22:vii20–8.PubMedGoogle Scholar
  154. 154.
    El Saghir NS et al. Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. Breast Cancer Res. 2011;20:S3–11.Google Scholar
  155. 155.
    Harford JB et al. Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative. Breast. 2011;20:S20–9.PubMedGoogle Scholar
  156. 156.
    Alwan A. Assessment of national capacity for NCD prevention and control. Geneva: WHO; 2001.Google Scholar
  157. 157.
    Alwan A et al. Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries. Lancet. 2010;376:1861–8.PubMedGoogle Scholar
  158. 158.
    Leowski J, Krishnan A. Capacity to control noncommunicable diseases in the countries of South-East Asia. Health Policy. 2009;92:43–8.PubMedGoogle Scholar
  159. 159.
    World Health Organization. Cancer control: knowledge into action. WHO guide for effective ­programmes; module 1. Planning. Geneva: WHO; 2006.Google Scholar
  160. 160.
    Sloan FA, Gelband H. Institute of Medicine Committee on Cancer Control in Low- and Middle-Income Countries. Cancer control opportunities in low- and middle-income countries: The National Academies Press; 2007.Google Scholar
  161. 161.
    Dye TD, Bogale S, Hobden C, Tilahun Y, Deressa T, Reeler A. Experience of initial symptoms of breast cancer and triggers for action in Ethiopia. Int J Breast Cancer. 2012;2012:908547.PubMedGoogle Scholar
  162. 162.
    Kim JJ, Salomon JA, Weinstein MC, Goldie SJ. Packaging health services when resources are limited: the example of a cervical cancer screening visit. PLoS Med. 2006;3:e434.PubMedGoogle Scholar
  163. 163.
    Mittra I et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer. 2010;126:976–84.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • William Kofi Bosu
    • 1
  • Terri L. Cornelison
    • 2
  • Brandy M. Heckman-Stoddard
    • 2
  1. 1.Disease Control and Prevention DepartmentGhana Health ServiceAccraGhana
  2. 2.Division of Cancer PreventionNational Cancer InstituteRockvilleUSA

Personalised recommendations